Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'July 7, 2026 3:52 PM Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'July 7, 2026 12:10 PM Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027'July 7, 2026 10:26 AM Form 8-K COMPASS Pathways plc For: Jul 07July 7, 2026 6:33 AM Compass Pathways reports 6-month data from second psilocybin Phase 3 trialJuly 7, 2026 6:30 AM Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable ProfileJuly 7, 2026 6:30 AM Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026July 6, 2026 8:30 AM